Allergic Manifestations and Dermatotoxicity
When prescribing sulfonamides, physicians must be aware of the high risk of allergic reactions. The clinical presentation of hypersensitivity can range from mild forms to conditions requiring discontinuation of therapy.
Basic manifestations include fever (drug fever), intense pruritus, and various cutaneous rashes.
A distinct and highly specific adverse effect is photosensitization. This phenomenon involves an abnormal increase in the patient's skin sensitivity to ultraviolet radiation. During a course of treatment, even brief exposure to direct sunlight can provoke pronounced skin reactions. Patients undergoing therapy are strongly advised to avoid sun exposure to prevent phototoxic damage.
Organ Toxicity and Systemic Disturbances
Sulfonamides exert systemic effects on the body, which can be accompanied by toxic damage to several vital systems simultaneously.
- Gastrointestinal tract: Patients frequently experience dyspeptic symptoms. Digestive disturbances can reduce treatment adherence and require symptomatic management.
- Liver: These drugs exhibit proven hepatotoxicity. Their toxic effect on hepatocytes dictates cautious use in individuals with pre-existing hepatobiliary disorders.
- Bone marrow and hematopoiesis: Hematotoxicity manifests as the suppression of various hematopoietic lineages. On a complete blood count, this may present as:
- Anemia (decreased red blood cell count);
- Leukopenia (decreased white blood cell count);
- Thrombocytopenia (decreased platelet count).
Renal Impairment: Mechanism and Prevention of Crystalluria
The nephrotoxicity of sulfonamides is most commonly mediated by crystalluria—the formation of insoluble crystals within the lumen of the urinary tract.
Condition for occurrence: The key risk factor is an acidic urine reaction (low pH). It is precisely in an acidic environment that sulfonamide molecules lose their solubility. Instead of being excreted freely in the urine, they precipitate out. The resulting microscopic crystals can mechanically traumatize the epithelial lining of the renal tubules and ureters.
Prevention: To avoid this complication, the urine pH must be artificially altered. Patients are prescribed high fluid intake with alkalizing agents. Consuming alkaline mineral water or a weak sodium bicarbonate solution alkalizes the urine. In an alkaline environment, the drugs remain in solution and safely leave the body.
Pediatric Practice: Risk of Kernicterus
The use of sulfonamides in neonatology (in newborn infants) is associated with the risk of a fatal complication—kernicterus, or bilirubin encephalopathy.
Pathogenesis of the complication: In human blood, bilirubin is transported bound to a protein, serum albumin. Sulfonamides have a high affinity for this protein and compete with bilirubin for binding sites. As a result, the drug aggressively displaces bilirubin from the protein complex. This leads to a sharp increase in the free (unbound), toxic bilirubin fraction in the infant's blood plasma.
Consequences: Free bilirubin easily crosses the immature blood-brain barrier of the newborn. Accumulating in brain structures, it causes severe toxic damage to the central nervous system.
Clinical conclusion: Due to the threat of irreversible brain damage, sulfonamides are strictly contraindicated in newborns.